Signe Regner Michaelsen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Signe Regner Michaelsen has a total of 144 co-authors. Here are the top co-authors by number of shared publications:
Hans Skovgaard Poulsen
DCCC Brain Tumor Center, Rigshospitalet, Copenhagen University Hospital , Copenhagen
12 shared publications- Ulrik Lassen
Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
9 shared publications - Hans Skovgaard Poulsen
The DCCC Brain Tumor Center, Rigshospitalet , Copenhagen
8 shared publications Helle Broholm
Department of Pathology, Rigshospitalet, Copenhagen University Hospital , Copenhagen
8 shared publicationsKirsten Grunnet
DCCC Brain Tumor Center, Rigshospitalet, Copenhagen University Hospital , Copenhagen
6 shared publications- Petra Hamerlik
Division of Cancer Sciences & Geoffrey Jefferson Brain Research Centre, University of Manchester, Manchester
6 shared publications
Latest Publications
- Open Access
- 12 January 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology Advances
- Vol. 8 (1)
Corticosteroid treatment modulates immune cell populations in the glioblastoma microenvironment
Background: Corticosteroids play a crucial role in alleviating tumor-associated edema in patients with brain tumors. However, their impact on the tumor microenvironment within glioblastoma remains largely unexplored. In the context of increasing interest in immunotherapy and limited clinical progress for glioblastoma patients, it is important to understand how corticosteroid therapy influences the immune microenvironment. Methods: This study involved 80 glioblastoma patients, 41 of whom received corticosteroids preoperatively and 39 who did not. The groups were balanced for key clinical prognostic parameters. Through immunohistochemical staining and image analysis-based software classifiers, we quantitatively assessed a broad marker panel covering immune, myeloid, hypoxia-related, and tumor-associated features of the glioblastoma microenvironment. Results: Our analysis revealed a more than 2-fold decrease in FOXP3+ regulatory T cells in glioblastoma tissue samples from patients who received corticosteroids. In dose-subgroup analyses, high-dose corticosteroid exposure was associated with increased CD68+ and CD204+ myeloid/macrophage-marker abundance. CD8 and CD4 T cell counts, as well as CD86, TMEM119, HIF-1α, PD-L1, and SOX2, remained similar across all groups. Conclusions: Our findings suggest that corticosteroid treatment is associated with selective changes in T cell and myeloid/macrophage-marker abundance within the tumor microenvironment. These findings highlight corticosteroid exposure as an important factor to consider when interpreting immune profiles and developing immune-based therapies in glioblastoma.
- 12 January 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology Advances
- Vol. 8 (1)
Open AccessCorticosteroid treatment modulates immune cell populations in the glioblastoma microenvironment
Background: Corticosteroids play a crucial role in alleviating tumor-associated edema in patients with brain tumors. However, their impact on the tumor microenvironment within glioblastoma remains largely unexplored. In the context of increasing interest in immunotherapy and limited clinical progress for glioblastoma patients, it is important to understand how corticosteroid therapy influences the immune microenvironment. Methods: This study involved 80 glioblastoma patients, 41 of whom received corticosteroids preoperatively and 39 who did not. The groups were balanced for key clinical prognostic parameters. Through immunohistochemical staining and image analysis-based software classifiers, we quantitatively assessed a broad marker panel covering immune, myeloid, hypoxia-related, and tumor-associated features of the glioblastoma microenvironment. Results: Our analysis revealed a more than 2-fold decrease in FOXP3+ regulatory T cells in glioblastoma tissue samples from patients who received corticosteroids. In dose-subgroup analyses, high-dose corticosteroid exposure was associated with increased CD68+ and CD204+ myeloid/macrophage-marker abundance. CD8 and CD4 T cell counts, as well as CD86, TMEM119, HIF-1α, PD-L1, and SOX2, remained similar across all groups. Conclusions: Our findings suggest that corticosteroid treatment is associated with selective changes in T cell and myeloid/macrophage-marker abundance within the tumor microenvironment. These findings highlight corticosteroid exposure as an important factor to consider when interpreting immune profiles and developing immune-based therapies in glioblastoma.
- Open Access
- 16 August 2025
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 28 (1) , 99-114
Clinical, radiological, and molecular insights into extracranial metastases from adult gliomas
Background: Extracranial metastases from adult gliomas cause diagnostic and therapeutic challenges and are generally poorly investigated. The aim of this study was to provide clinical and molecular insights into glioma metastasis. Methods: Our cohort comprised tumor tissue from 16 glioma patients with metastasis (14 glioblastomas and 2 lower-grade gliomas). Paired primary tumors, recurrences, and metastases were investigated by DNA sequencing, genome-wide DNA methylation profiling, RNA sequencing, immunohistochemistry, and MRI examinations. Results: The metastases were distributed across the scalp/upper neck (8), lymph nodes (5), bone (2), and liver (1). Six out of 14 glioblastomas displayed significant sarcomatous differentiation, consistent with the otherwise rare histological subtype gliosarcoma. A majority of the scalp lesions were connected to an intracranial brain tumor via tumor extension through craniotomy burr holes, proposing that surgery is a contributing factor to tumor spread. Next-generation sequencing-based mutational analysis revealed that the true metastases originated from the primary tumors and not later recurrences. We observed tumor plasticity as the tumors progressed to metastasis, demonstrated by changes in epigenetic methylation classes and transcriptional subtypes. Despite different locations of metastases in the cohort, the immune cell composition in the tumor microenvironment remained overall stable during tumor progression. Conclusion: Metastases from adult gliomas originate from the primary brain tumors and not later recurrences. While RNA sequencing and methylation profiling revealed tumor plasticity during progression to metastasis, the immune cell composition remained overall stable.
- 16 August 2025
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 28 (1) , 99-114
Open AccessClinical, radiological, and molecular insights into extracranial metastases from adult gliomas
Background: Extracranial metastases from adult gliomas cause diagnostic and therapeutic challenges and are generally poorly investigated. The aim of this study was to provide clinical and molecular insights into glioma metastasis. Methods: Our cohort comprised tumor tissue from 16 glioma patients with metastasis (14 glioblastomas and 2 lower-grade gliomas). Paired primary tumors, recurrences, and metastases were investigated by DNA sequencing, genome-wide DNA methylation profiling, RNA sequencing, immunohistochemistry, and MRI examinations. Results: The metastases were distributed across the scalp/upper neck (8), lymph nodes (5), bone (2), and liver (1). Six out of 14 glioblastomas displayed significant sarcomatous differentiation, consistent with the otherwise rare histological subtype gliosarcoma. A majority of the scalp lesions were connected to an intracranial brain tumor via tumor extension through craniotomy burr holes, proposing that surgery is a contributing factor to tumor spread. Next-generation sequencing-based mutational analysis revealed that the true metastases originated from the primary tumors and not later recurrences. We observed tumor plasticity as the tumors progressed to metastasis, demonstrated by changes in epigenetic methylation classes and transcriptional subtypes. Despite different locations of metastases in the cohort, the immune cell composition in the tumor microenvironment remained overall stable during tumor progression. Conclusion: Metastases from adult gliomas originate from the primary brain tumors and not later recurrences. While RNA sequencing and methylation profiling revealed tumor plasticity during progression to metastasis, the immune cell composition remained overall stable.
- Top Cited PapersOpen Access
- 9 September 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-14
Glioblastoma cells increase expression of notch signaling and synaptic genes within infiltrated brain tissue
Glioblastoma remains one of the deadliest brain malignancies. First-line therapy consists of maximal surgical tumor resection, accompanied by chemotherapy and radiotherapy. Malignant cells escape surgical resection by migrating into the surrounding healthy brain tissue, where they give rise to the recurrent tumor. Based on gene expression, tumor cores can be subtyped into mesenchymal, proneural, and classical tumors, each being associated with differences in genetic alterations and cellular composition. In contrast, the adjacent brain parenchyma where infiltrating malignant cells escape surgical resection is less characterized in patients. Using spatial transcriptomics (n = 11), we show that malignant cells within proneural or mesenchymal tumor cores display spatially organized differences in gene expression, although such differences decrease within the infiltrated brain tissue. Malignant cells residing in infiltrated brain tissue have increased expression of genes related to neurodevelopmental pathways and glial cell differentiation. Our findings provide an updated view of the spatial landscape of glioblastomas and further our understanding of the malignant cells that infiltrate the healthy brain, providing new avenues for the targeted therapy of these cells after surgical resection.
- 9 September 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-14
Top Cited PapersOpen AccessGlioblastoma cells increase expression of notch signaling and synaptic genes within infiltrated brain tissue
Glioblastoma remains one of the deadliest brain malignancies. First-line therapy consists of maximal surgical tumor resection, accompanied by chemotherapy and radiotherapy. Malignant cells escape surgical resection by migrating into the surrounding healthy brain tissue, where they give rise to the recurrent tumor. Based on gene expression, tumor cores can be subtyped into mesenchymal, proneural, and classical tumors, each being associated with differences in genetic alterations and cellular composition. In contrast, the adjacent brain parenchyma where infiltrating malignant cells escape surgical resection is less characterized in patients. Using spatial transcriptomics (n = 11), we show that malignant cells within proneural or mesenchymal tumor cores display spatially organized differences in gene expression, although such differences decrease within the infiltrated brain tissue. Malignant cells residing in infiltrated brain tissue have increased expression of genes related to neurodevelopmental pathways and glial cell differentiation. Our findings provide an updated view of the spatial landscape of glioblastomas and further our understanding of the malignant cells that infiltrate the healthy brain, providing new avenues for the targeted therapy of these cells after surgical resection.
- Open Access
- 1 September 2022
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 24 (Supplement) , ii29
P02.03.B Drug repurposing screen reveals glioblastoma cell line susceptibility to statins
The standard therapy for glioblastoma patients is tumor resection followed by radiotherapy and temozolomide chemotherapy. Although glioblastoma has been extensively molecularly profiled along with other cancers, this knowledge has not yet been translated into improved survival outcomes. We used a bioinformatics approach to identify potential novel therapeutic strategies for glioblastoma. Objectives: Comprehensive online datasets which have assessed up to 1376 cancer cell lines in multiple ways were interrogated to identify potential drug candidates for glioblastoma. Datasets included were from the cancer cell line encyclopedia (mRNA expression), the Achillies project (cell viability following Crispr-Cas9 knockout) and PRISM (drug treatment). A t-test comparing cell viability of glioblastoma cell lines versus other cancers was used to identify potential drug candidates, followed by the use of multiple statistical tools to investigate potential mechanism of action and status of biomarkers. Fluvastatin and pitavastatin were amongst the drugs with the most significant effects against glioblastoma cell lines while also being FDA approved. These effects were found in both glioblastoma cells and other cancer types with a mesenchymal-like expression phenotype. The anti-cancer properties of statins have previously been attributed to the inhibition of HMG-Coa reductase. Here, we found their effects correlated with the gene knockout of UBIAD1. We tested the effects of statins on patient-derived glioblastoma cell lines with a mesenchymal (n = 2) and non-mesenchymal phenotype (n=2). Mesenchymal-like glioblastoma cells lines were found to be more susceptible to statins. Statins appeared to be especially effective against glioblastoma lines and the effect could be linked to the direct or indirect inhibition of UBIAD1. In vitro validation of this finding is ongoing.
- 1 September 2022
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 24 (Supplement) , ii29
Open AccessP02.03.B Drug repurposing screen reveals glioblastoma cell line susceptibility to statins
The standard therapy for glioblastoma patients is tumor resection followed by radiotherapy and temozolomide chemotherapy. Although glioblastoma has been extensively molecularly profiled along with other cancers, this knowledge has not yet been translated into improved survival outcomes. We used a bioinformatics approach to identify potential novel therapeutic strategies for glioblastoma. Objectives: Comprehensive online datasets which have assessed up to 1376 cancer cell lines in multiple ways were interrogated to identify potential drug candidates for glioblastoma. Datasets included were from the cancer cell line encyclopedia (mRNA expression), the Achillies project (cell viability following Crispr-Cas9 knockout) and PRISM (drug treatment). A t-test comparing cell viability of glioblastoma cell lines versus other cancers was used to identify potential drug candidates, followed by the use of multiple statistical tools to investigate potential mechanism of action and status of biomarkers. Fluvastatin and pitavastatin were amongst the drugs with the most significant effects against glioblastoma cell lines while also being FDA approved. These effects were found in both glioblastoma cells and other cancer types with a mesenchymal-like expression phenotype. The anti-cancer properties of statins have previously been attributed to the inhibition of HMG-Coa reductase. Here, we found their effects correlated with the gene knockout of UBIAD1. We tested the effects of statins on patient-derived glioblastoma cell lines with a mesenchymal (n = 2) and non-mesenchymal phenotype (n=2). Mesenchymal-like glioblastoma cells lines were found to be more susceptible to statins. Statins appeared to be especially effective against glioblastoma lines and the effect could be linked to the direct or indirect inhibition of UBIAD1. In vitro validation of this finding is ongoing.
- Open Access
- 15 June 2022
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 82 (12_Supplem) , 1842
Abstract 1842: Drug repurposing screen reveals glioblastoma cell line susceptibility to statins
Background: The standard therapy for glioblastoma patients is tumor resection followed by radiotherapy and temozolomide chemotherapy. Although glioblastoma has been extensively molecularly profiled along with other cancers, this knowledge has not yet been translated into improved survival outcomes. We used a bioinformatics approach to identify potential novel therapeutic strategies for glioblastoma. Objectives: Comprehensive online datasets which have assessed up to 1376 cancer cell lines in multiple ways were interrogated to identify potential drug candidates for glioblastoma. Methods: Datasets included were from the cancer cell line encyclopedia (mRNA expression), the Achillies project (cell viability following Crispr-Cas9 knockout) and PRISM (drug treatment). A t-test comparing cell viability of glioblastoma cell lines versus other cancers was used to identify potential drug candidates, followed by the use of multiple statistical tools to investigate potential mechanism of action and status of biomarkers. Results: Fluvastatin and pitavastatin were amongst the drugs with the most significant effects against glioblastoma cell lines while also being FDA approved. These effects were found in both glioblastoma cells and other cancer types with a mesenchymal-like expression phenotype. The anti-cancer properties of statins have previously been attributed to the inhibition of HMG-Coa reductase. Here, we found their effects correlated with the gene knockout of UBIAD1, which participates in non-mitochondrial ubiquinone and menaquinone-4 synthesis. We tested the effects of statins on patient-derived glioblastoma cell lines with a mesenchymal (n = 2) and non-mesenchymal phenotype (n=2). Mesenchymal-like glioblastoma cells lines were found to be particularly susceptible to multiple statins. Conclusion: Statins appeared to be especially effective against glioblastoma lines and the effect could be linked to the direct or indirect inhibition of UBIAD1. In vitro validation of this finding is ongoing. Citation Format: Dylan S. Harwood, Signe R. Michaelsen, Bjarne W. Kristensen. Drug repurposing screen reveals glioblastoma cell line susceptibility to statins [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 1842.
- 15 June 2022
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 82 (12_Supplem) , 1842
Open AccessAbstract 1842: Drug repurposing screen reveals glioblastoma cell line susceptibility to statins
Background: The standard therapy for glioblastoma patients is tumor resection followed by radiotherapy and temozolomide chemotherapy. Although glioblastoma has been extensively molecularly profiled along with other cancers, this knowledge has not yet been translated into improved survival outcomes. We used a bioinformatics approach to identify potential novel therapeutic strategies for glioblastoma. Objectives: Comprehensive online datasets which have assessed up to 1376 cancer cell lines in multiple ways were interrogated to identify potential drug candidates for glioblastoma. Methods: Datasets included were from the cancer cell line encyclopedia (mRNA expression), the Achillies project (cell viability following Crispr-Cas9 knockout) and PRISM (drug treatment). A t-test comparing cell viability of glioblastoma cell lines versus other cancers was used to identify potential drug candidates, followed by the use of multiple statistical tools to investigate potential mechanism of action and status of biomarkers. Results: Fluvastatin and pitavastatin were amongst the drugs with the most significant effects against glioblastoma cell lines while also being FDA approved. These effects were found in both glioblastoma cells and other cancer types with a mesenchymal-like expression phenotype. The anti-cancer properties of statins have previously been attributed to the inhibition of HMG-Coa reductase. Here, we found their effects correlated with the gene knockout of UBIAD1, which participates in non-mitochondrial ubiquinone and menaquinone-4 synthesis. We tested the effects of statins on patient-derived glioblastoma cell lines with a mesenchymal (n = 2) and non-mesenchymal phenotype (n=2). Mesenchymal-like glioblastoma cells lines were found to be particularly susceptible to multiple statins. Conclusion: Statins appeared to be especially effective against glioblastoma lines and the effect could be linked to the direct or indirect inhibition of UBIAD1. In vitro validation of this finding is ongoing. Citation Format: Dylan S. Harwood, Signe R. Michaelsen, Bjarne W. Kristensen. Drug repurposing screen reveals glioblastoma cell line susceptibility to statins [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 1842.
- Open Access
- 8 July 2019
- Published by Impact Journals, LLC in Oncotarget
- Vol. 10 (43) , 4397-4406
Cell-free DNA in newly diagnosed patients with glioblastoma – a clinical prospective feasibility study
Oncotarget | https://doi.org/10.18632/oncotarget.27030 Dorte Schou Nørøxe, Olga Østrup, Christina Westmose Yde, Lise Barlebo Ahlborn, Finn Cilius Nielsen, Signe Regner Michaelsen, Vibeke Andrée Larsen, Jane...
- 8 July 2019
- Published by Impact Journals, LLC in Oncotarget
- Vol. 10 (43) , 4397-4406
Open AccessCell-free DNA in newly diagnosed patients with glioblastoma – a clinical prospective feasibility study
Oncotarget | https://doi.org/10.18632/oncotarget.27030 Dorte Schou Nørøxe, Olga Østrup, Christina Westmose Yde, Lise Barlebo Ahlborn, Finn Cilius Nielsen, Signe Regner Michaelsen, Vibeke Andrée Larsen, Jane...
- Open Access
- 18 June 2019
- Published by Impact Journals, LLC in Oncotarget
- Vol. 10 (40) , 3988-3990
VEGF-C as a putative therapeutic target in cancer
- 18 June 2019
- Published by Impact Journals, LLC in Oncotarget
- Vol. 10 (40) , 3988-3990
Open AccessVEGF-C as a putative therapeutic target in cancer
- Open Access
- 27 December 2018
- Published by Wiley in Clinical Case Reports
- Vol. 7 (2) , 289-294
Extracranial metastases in glioblastoma—Two case stories
Key Clinical Message: The clinician should always consider extracranial metastases in glioblastoma. Increased risk factors are young age at diagnosis, histology of gliosarcoma, and prior intracranial tumor surgery. Clinical guidelines are needed for this rare event, including consideration for prophylactic intervention.
- 27 December 2018
- Published by Wiley in Clinical Case Reports
- Vol. 7 (2) , 289-294
Open AccessExtracranial metastases in glioblastoma—Two case stories
Key Clinical Message: The clinician should always consider extracranial metastases in glioblastoma. Increased risk factors are young age at diagnosis, histology of gliosarcoma, and prior intracranial tumor surgery. Clinical guidelines are needed for this rare event, including consideration for prophylactic intervention.
- Open Access
- 25 June 2018
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 20 (11) , 1462-1474
VEGF-C sustains VEGFR2 activation under bevacizumab therapy and promotes glioblastoma maintenance
Background: Glioblastoma ranks among the most lethal cancers, with current therapies offering only palliation. Paracrine vascular endothelial growth factor (VEGF) signaling has been targeted using anti-angiogenic agents, whereas autocrine VEGF/VEGF receptor 2 (VEGFR2) signaling is poorly understood. Bevacizumab resistance of VEGFR2-expressing glioblastoma cells prompted interrogation of autocrine VEGF-C/VEGFR2 signaling in glioblastoma. Methods: Autocrine VEGF-C/VEGFR2 signaling was functionally investigated using RNA interference and exogenous ligands in patient-derived xenograft lines and primary glioblastoma cell cultures in vitro and in vivo. VEGF-C expression and interaction with VEGFR2 in a matched pre- and post-bevacizumab treatment cohort were analyzed by immunohistochemistry and proximity ligation assay. Results: VEGF-C was expressed by patient-derived xenograft glioblastoma lines, primary cells, and matched surgical specimens before and after bevacizumab treatment. VEGF-C activated autocrine VEGFR2 signaling to promote cell survival, whereas targeting VEGF-C expression reprogrammed cellular transcription to attenuate survival and cell cycle progression. Supporting potential translational significance, targeting VEGF-C impaired tumor growth in vivo, with superiority to bevacizumab treatment. Conclusions: Our results demonstrate VEGF-C serves as both a paracrine and an autocrine pro-survival cytokine in glioblastoma, promoting tumor cell survival and tumorigenesis. VEGF-C permits sustained VEGFR2 activation and tumor growth, where its inhibition appears superior to bevacizumab therapy in improving tumor control.
- 25 June 2018
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 20 (11) , 1462-1474
Open AccessVEGF-C sustains VEGFR2 activation under bevacizumab therapy and promotes glioblastoma maintenance
Background: Glioblastoma ranks among the most lethal cancers, with current therapies offering only palliation. Paracrine vascular endothelial growth factor (VEGF) signaling has been targeted using anti-angiogenic agents, whereas autocrine VEGF/VEGF receptor 2 (VEGFR2) signaling is poorly understood. Bevacizumab resistance of VEGFR2-expressing glioblastoma cells prompted interrogation of autocrine VEGF-C/VEGFR2 signaling in glioblastoma. Methods: Autocrine VEGF-C/VEGFR2 signaling was functionally investigated using RNA interference and exogenous ligands in patient-derived xenograft lines and primary glioblastoma cell cultures in vitro and in vivo. VEGF-C expression and interaction with VEGFR2 in a matched pre- and post-bevacizumab treatment cohort were analyzed by immunohistochemistry and proximity ligation assay. Results: VEGF-C was expressed by patient-derived xenograft glioblastoma lines, primary cells, and matched surgical specimens before and after bevacizumab treatment. VEGF-C activated autocrine VEGFR2 signaling to promote cell survival, whereas targeting VEGF-C expression reprogrammed cellular transcription to attenuate survival and cell cycle progression. Supporting potential translational significance, targeting VEGF-C impaired tumor growth in vivo, with superiority to bevacizumab treatment. Conclusions: Our results demonstrate VEGF-C serves as both a paracrine and an autocrine pro-survival cytokine in glioblastoma, promoting tumor cell survival and tumorigenesis. VEGF-C permits sustained VEGFR2 activation and tumor growth, where its inhibition appears superior to bevacizumab therapy in improving tumor control.
- Open Access
- 28 February 2018
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 19 (3) , 679
DNA Methylation Levels of the ELMO Gene Promoter CpG Islands in Human Glioblastomas
Complete surgical resection of glioblastoma is difficult due to the invasive nature of this primary brain tumor, for which the molecular mechanisms behind remain poorly understood. The three human ELMO genes play key roles in cellular motility, and have been linked to metastasis and poor prognosis in other cancer types. The aim of this study was to investigate methylation levels of the ELMO genes and their correlation to clinical characteristics and outcome in patients diagnosed with glioblastoma. To measure DNA methylation levels we designed pyrosequencing assays targeting the promoter CpG island of each the ELMO genes. These were applied to diagnostic tumor specimens from a well-characterized cohort of 121 patients who received standard treatment consisting of surgery, radiation therapy, plus concomitant and adjuvant chemotherapy. The promoter methylation levels of ELMO1 and ELMO2 were generally low, whereas ELMO3 methylation levels were high, in the tumor biopsies. Thirteen, six, and 18 biopsies were defined as aberrantly methylated for ELMO1, ELMO2, and ELMO3, respectively. There were no significant associations between the methylation status of any of the ELMO gene promoter CpG islands and overall survival, progression-free survival, and clinical characteristics of the patients including intracranial tumor location. Therefore, the methylation status of the ELMO gene promoter CpG islands is unlikely to have prognostic value in glioblastoma.
- 28 February 2018
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 19 (3) , 679
Open AccessDNA Methylation Levels of the ELMO Gene Promoter CpG Islands in Human Glioblastomas
Complete surgical resection of glioblastoma is difficult due to the invasive nature of this primary brain tumor, for which the molecular mechanisms behind remain poorly understood. The three human ELMO genes play key roles in cellular motility, and have been linked to metastasis and poor prognosis in other cancer types. The aim of this study was to investigate methylation levels of the ELMO genes and their correlation to clinical characteristics and outcome in patients diagnosed with glioblastoma. To measure DNA methylation levels we designed pyrosequencing assays targeting the promoter CpG island of each the ELMO genes. These were applied to diagnostic tumor specimens from a well-characterized cohort of 121 patients who received standard treatment consisting of surgery, radiation therapy, plus concomitant and adjuvant chemotherapy. The promoter methylation levels of ELMO1 and ELMO2 were generally low, whereas ELMO3 methylation levels were high, in the tumor biopsies. Thirteen, six, and 18 biopsies were defined as aberrantly methylated for ELMO1, ELMO2, and ELMO3, respectively. There were no significant associations between the methylation status of any of the ELMO gene promoter CpG islands and overall survival, progression-free survival, and clinical characteristics of the patients including intracranial tumor location. Therefore, the methylation status of the ELMO gene promoter CpG islands is unlikely to have prognostic value in glioblastoma.